Posted on

fda cbd meeting

Fda cbd meeting

Moderator: Leyla Sahin, MD. Senior Medical Officer, Division of Pediatric and Maternal Health, Office of New Drugs, Center for Drug Evaluation and Research, FDA

Cinnamon Bidwell, PhD. Assistant Professor, Institute of Cognitive Science and Department of Psychology and Neuroscience; Director, Center for Research and Education Addressing Cannabis and Health (REACH), University of Colorado, Boulder

Yasmin Hurd, PhD. Ward Coleman Chair of Translational Neuroscience and Professor of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai; Director of the Addiction Institute, Mount Sinai Behavioral Health System


Scott Parnell, PhD. Assistant Professor, Cell Biology and Physiology, University of North Carolina, Chapel Hill

Panel 4: Government Agency Perspectives on CBD Research and Evaluation

Ryan Vandrey, PhD. Professor, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine

A webcast recording is available in four distinct segments. Each segment is in order based on the agenda.

Dr. Sharpless’ opening remarks are now available.

The Food and Drug Administration held a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. See the Federal Register notice for more information.

The transcript is available for the Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds Public Hearing.

Webcast Recording


Fda cbd meeting

CDC in September issued a health advisory on delta-8 THC, warning about the growing availability of cannabis products containing delta-8 THC and the potential for adverse events due to inadequate labeling of products containing THC and CBD.

HHS did not immediately respond Tuesday to a request for comment concerning the letter, which also was sent to FDA Acting Commissioner Janet Woodcock.

CBD bills, citizen petitions

FDA also advised CRN in November 2020 that it needed more time to review its citizen petition for the same reasons it cited in the letter to CHPA.

“The continued lack of regulatory clarity along with insufficient oversight around hemp and hemp-derived CBD has led to bad actors entering the marketplace, exposing consumers to potentially unsafe products that contain illegal synthetic ingredients like delta-8 THC and lack consistency in product quality,” David Spangler, CHPA’s senior vice president of legal, government affairs and policy, said via email.

Editorial credit: CHRISTOPHER E ZIMMER /